Stada down 20%, but still hopes for good year
Stada Arzneimittel has reported a 20% year-on-year plunge in profit for the first quarter of 2009, due to "the especially difficult framework conditions of the global financial and economic crisis." However the firm also notes that the results achieved were in the upper regions of its predictions.
The German generic drugmaker generated 375.9 million euros ($512.4 million) in revenue, down 6%, while R&D costs increased 6% to 11.1 million euros. The company's net income was 24.1 million euros, or 0.41 euros per share, versus 30.3 million euros, or 0.52 euros per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze